CTAS are distinguished from most commercial agreements in that the intellectual property generated is usually data that can be submitted to a regulatory authority to obtain the authorization of the drug in question. In most cases, they are unlikely to result in potentially patentable subject matter, but intellectual property remains of paramount importance in such agreements. . . .